Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study

再生障碍性贫血、骨髓增生异常综合征和阵发性睡眠性血红蛋白尿症中对 LGL 白血病特异性表位的血清反应性:骨髓衰竭联盟研究的结果

阅读:5
作者:Susan Bell Nyland, Daniel J Krissinger, Michael J Clemente, Rosalyn B Irby, Kendall Thomas Baab, Nancy Ruth Jarbadan, Lubomir Sokol, Eric Schaefer, Jason Liao, David Cuthbertson, Pearlie Epling-Burnette, Ronald Paquette, Alan F List, Jaroslaw P Maciejewski, Thomas P Loughran Jr

Abstract

Large granular lymphocyte (LGL) leukemia is characterized by clonal expansion of antigen-activated cytotoxic T cells (CTL). Patients frequently exhibit seroreactivity against a human T-cell leukemia virus (HTLV) epitope, BA21. Aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome are bone marrow failure diseases that can also be associated with similar aberrant CTL activation (LGL-BMF). We identified a BA21 peptide that was specifically reactive with LGL leukemia sera and found significantly elevated antibody reactivity against the same peptide in LGL-BMF sera. This finding of shared seroreactivity in LGL-BMF conditions and LGL leukemia suggests that these diseases might share a common pathogenesis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。